Courses

Strategies for the Long-Term Treatment of SMA to Optimize Patient Outcomes

Strategies for the Long-Term Treatment of SMA to Optimize Patient Outcomes

In this module, Perry Shieh, MD, PhD, along with Claudia Chiriboga, MD, MPH, course chair, will review strategies for the long-term treatment of SMA to optimize patient outcomes. The expert faculty will discuss long-term efficacy and safety data in order to develop effective SMA patient management strategies with the interprofessional team and identify available resources for optimal care while the ...
View Course
The Benefits and Long-Term Effects of Presymptomatic Treatment

The Benefits and Long-Term Effects of Presymptomatic Treatment

In this module, Julie Parsons, MD, along with Claudia Chiriboga, MD, MPH, course chair, will review the benefits and long-term effects of presymptomatic treatment for patients with spinal muscular atrophy (SMA). The faculty will discuss the benefits of early disease diagnosis and how to implement presymptomatic treatment in infants with SMA. Upon completion of this 30-minute module, clinicians will gain ...
View Course
Review of Current and Emerging Therapeutic Options for Patients with SMA

Review of Current and Emerging Therapeutic Options for Patients with SMA

In this module, Basil Darras, MD, along with Claudia Chiriboga, MD, MPH, course chair, will analyze current and emerging therapeutic options for patients with spinal muscular atrophy (SMA). The faculty will review recent data of both available and investigational therapeutic options for the treatment of patients with SMA. Upon completion of this 30-minute module, learners will gain insight into current ...
View Course
Applications of Genetic Screening for SMA

Applications of Genetic Screening for SMA

In this module, Wendy Chung, MD, PhD, along with Claudia Chiriboga, MD, MPH, course chair, will review the applications of genetic screening for patients with spinal musical atrophy (SMA). The faculty will discuss updates in screening techniques, as well as advances in genetic testing for infants with SMA. Upon completion of this 30-minute module, clinicians will be better equipped with ...
View Course
Virtual CureSMA 2020 Data Review and Analyses

Virtual CureSMA 2020 Data Review and Analyses

In this module, John Brandsema MD, along with Claudia Chiriboga, MD, MPH, course chair, will review information released at the Virtual CureSMA Conference 2020. Dr. Brandsema will provide an in-depth overview of recent clinical trial data of current and emerging therapeutics for SMA, and the expert faculty will dive into a discussion on the details of these clinical trials and ...
View Course
Managing SMA Patients During the COVID-19 Pandemic – CureSMA

Managing SMA Patients During the COVID-19 Pandemic – CureSMA

In this module, Oscar Henry Mayer, MD, along with Claudia Chiriboga, MD, MPH, course chair, will discuss strategies for managing spinal muscular atrophy (SMA) patients during the COVID-19 pandemic. Current clinical recommendations from CureSMA for the management of patients with SMA will be reviewed during the interview segment. Best practices for avoiding care disruption for SMA patients during the COVID-19 ...
View Course
Advances in Sphingosine-1-phosphate (S1P) Therapeutics to Improve Outcomes in Patients with Inflammatory Bowel Disease

Advances in Sphingosine-1-phosphate (S1P) Therapeutics to Improve Outcomes in Patients with Inflammatory Bowel Disease

This CME activity will highlight advances in sphinogosine-1-phosphate (S1P) therapeutics to improve outcomes in patients with inflammatory bowel disease. The expert faculty, led by Dr. William Sandborn, will discuss how sphingosine-1-phosphate (S1P) receptor modulators are utilized as a therapeutic target to reduce inflammation in patients with inflammatory bowel disease (IBD). Recent and emerging clinical trial data on the safety and ...
View Course
Clinical Trial Analysis of BRAF and Anti-PD-1 Targeted Therapeutic Options for Colorectal Cancer

Clinical Trial Analysis of BRAF and Anti-PD-1 Targeted Therapeutic Options for Colorectal Cancer

In this module, Ryan B. Corcoran, MD PhD, along with Scott Kopetz, MD, PhD, course chair, will highlight current clinical trial data for BRAF and Anti-PD-1 targeted therapeutic options in the colorectal cancer treatment landscape. The expert faculty will provide an in-depth review of novel studies by analyzing study populations, methods and results, as well as providing key takeaways for ...
View Course
Targeted Anti-PD-1-based Therapies and Adverse Event Mitigation to Improve Outcomes in Patients with CRC

Targeted Anti-PD-1-based Therapies and Adverse Event Mitigation to Improve Outcomes in Patients with CRC

In this module, Michael J. Overman, MD, along with Scott Kopetz, MD, PhD, course chair, will review clinical trial data of approved and emerging targeted Anti-PD-1-based therapies for the treatment of patients with colorectal cancer, debating the clinical relevance of each in a discussion-based format. The toxicity spectrum of immune-related adverse events will be covered, along with kinetics. Current treatment ...
View Course
Colorectal Cancer Update: Prevalence, Screening, Biomarker and Genomic Testing, and Therapeutic Targets

Colorectal Cancer Update: Prevalence, Screening, Biomarker and Genomic Testing, and Therapeutic Targets

In this module, Jonathan Loree, MD, MS, along with Scott Kopetz, MD, PhD, course chair, will first provide a brief overview of the history and prevalence of colorectal cancer, as well as best practices for screening. Following, the expert faculty will review the role of clinically relevant biomarkers in metastatic colorectal cancer. Strategies for detecting and managing various prevalent mutations ...
View Course